Armadin, founded by cybersecurity veteran Kevin Mandia, raised $255.5 million in a Series B funding round, pushing its valuation above $2.5 billion just months after its public launch. The company uses swarms of AI agents to simulate cyberattacks in a controlled environment, helping enterprises and government agencies identify vulnerabilities before real attackers can exploit them. Led by investors including Andreessen Horowitz, Accel, and Google Ventures, Armadin plans to use the funds to expand its platform, enhance AI research, and grow its sales efforts. This proactive approach contrasts with Mandia's previous company, Mandiant, which focused on incident response after breaches occur.
Kevin Mandia's Armadin raising $255.5 million provides context for today's market snapshot. For readers following cryptocurrency markets, here is Pluang's data as of Oct 02, 2026 05:02 WIB: Of 50 major cryptocurrencies priced on Pluang, 26 rose and 23 fell today. Notable moves include XLM (Stellar) down 3.33% at Rp3.922 with a typical hold time of 84 days and Pluang order activity showing 9% Sell / 91% Buy, LTC (Litecoin) up 3.13% at Rp1.229.292 with a typical hold time of 78 days and order activity 47% Sell / 53% Buy, and SAND (The Sandbox) up 3.02% at Rp797 with a typical hold time of 123 days and order activity 76% Sell / 24% Buy.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
